Risk-sharing agreements have been suggested as a tool to accelerate access to new innovative medicines by reducing risk for the stakeholders. Especially uncertainty in clinical effectiveness, safety and financial consequences for patients and buyers are aimed at being reduced. This article outlines the concept, a terminology and advantages and disadvantages of the agreements. We argue that all risk-sharing agreements involve both advantages and disadvantages among relevant stakeholders.